In patients with other solid tumors presenting HER2 overexpression, such as colorectal, biliary tract, non-small-cell lung, and bladder cancers, other HER2-targeted therapies are also being evaluated [28]. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.